Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2021 Aug 4:2021.08.02.21261516.
doi: 10.1101/2021.08.02.21261516.

COVID19 vaccine type and humoral immune response in patients receiving dialysis

Pablo Garcia #  1 , Shuchi Anand #  1 , Jialin Han  1 , Maria Montez-Rath  1 , Sumi Sun  2 , Tiffany Shang  2 , Julie Parsonnet  3 , Glenn M Chertow  4 , Brigitte Schiller #  2 , Graham Abra #  2
Affiliations

COVID19 vaccine type and humoral immune response in patients receiving dialysis

Pablo Garcia et al. medRxiv. .

Update in

Abstract

Background: Patients on dialysis vaccinated with the attenuated adenovirus SARS-CoV-2 vaccine might mount an impaired response to vaccination.

Methods: We evaluated the humoral vaccination response among 2,099 fully vaccinated patients receiving dialysis. We used commercially available assays (Siemens) to assess prevalence of no response or diminished response to COVID-19 vaccination by vaccine type. We defined "no seroconversion" as lack of change from negative to positive in total RBD Ig antibody, no detectable response on semiquantitative RBD IgG antibody (index value <1) as "no RBD IgG response", and a semiquantitative RBD IgG index value <10 as "diminished RBD IgG response".

Results: Of the 2,099 fully vaccinated patients on dialysis, the proportion receiving the mRNA1273, BNT162b2, and Ad26.COV2.S were 62% (n=1316), 20% (n=416) and 18% (n=367), respectively. A third (33.3%) of patients receiving the attenuated adenovirus Ad26.COV2.S vaccine failed to seroconvert and an additional 36% had no detectable or diminished IgG response even 28-60 days post vaccination.

Conclusion: One in three fully vaccinated patients receiving dialysis had evidence of an impaired immune response to the attenuated adenovirus Ad26.COV2.S vaccine.

Keywords: ESRD; SARS-CoV-2; covid-19; dialysis; vaccine.

PubMed Disclaimer

References

    1. De Meester J, De Bacquer D, Naesens M, et al. Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry Study. J Am Soc Nephrol. Feb 2021;32(2):385–396. doi:10.1681/ASN.2020060875 - DOI - PMC - PubMed
    1. Anand S, Montez-Rath M, Han J, et al. Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis. J Am Soc Nephrol. Jun 11 2021;doi:10.1681/ASN.2021050611 - DOI - PMC - PubMed
    1. Siemens Healthineers. SARS-CoV-2 Total Assay. https://statichealthcaresiemenscom/siemens_hwem-hwem_ssxa_websites-conte.... Accessed July 10, 2020 2020;
    1. Siemens Healthcare Diagnostics Inc. ADVIA Centaur XP and ADVIA Centaur XPT Systems. 2020. Accessed June 28, 2021. https://www.fda.gov/media/140704/download
    1. Siemens Healthcare Diagnostics Inc. Atellica IM Analyzer. 2021. Accessed June 28, 2021. https://www.fda.gov/media/146931/download

Publication types